These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30603390)

  • 1. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy.
    Yun JW; Ahn JB; Kwon E; Ahn JH; Park HW; Heo H; Park JS; Kim H; Paek SH; Kang BC
    Tissue Eng Regen Med; 2016 Feb; 13(1):100-109. PubMed ID: 30603390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.
    Ando K; Obayashi S; Nagai Y; Oh-Nishi A; Minamimoto T; Higuchi M; Inoue T; Itoh T; Suhara T
    PLoS One; 2012; 7(10):e46371. PubMed ID: 23056291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
    Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
    Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
    Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
    Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model.
    Hikishima K; Ando K; Komaki Y; Kawai K; Yano R; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Neuroscience; 2015 Aug; 300():585-92. PubMed ID: 26012491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations.
    Ando K; Inoue T; Hikishima K; Komaki Y; Kawai K; Inoue R; Nishime C; Nishinaka E; Urano K; Okano H
    Behav Pharmacol; 2020 Feb; 31(1):45-60. PubMed ID: 31625972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.
    Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC
    NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.
    Zeng BY; Iravani MM; Lin ST; Irifune M; Kuoppamäki M; Al-Barghouthy G; Smith L; Jackson MJ; Rose S; Medhurst AD; Jenner P
    Eur J Neurosci; 2006 Apr; 23(7):1766-74. PubMed ID: 16623833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).
    Phillips KA; Ross CN; Spross J; Cheng CJ; Izquierdo A; Biju KC; Chen C; Li S; Tardif SD
    Behav Brain Res; 2017 May; 325(Pt A):51-62. PubMed ID: 28219749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care.
    Yun JW; Ahn JB; Kang BC
    Lab Anim Res; 2015 Dec; 31(4):155-65. PubMed ID: 26755918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.